US 11,744,827 B2
Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
James Allen Cardelli, Shreveport, LA (US); Magdalena Liliana Circu, Shreveport, LA (US); Samantha Sarah Dykes, Shreveport, LA (US); and Hazem Edmond El-Osta, Shreveport, LA (US)
Assigned to Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
Filed by Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
Filed on Jun. 29, 2020, as Appl. No. 16/916,061.
Application 16/916,061 is a division of application No. 15/571,917, granted, now 10,695,338, previously published as PCT/US2016/031181, filed on May 6, 2016.
Claims priority of provisional application 62/158,212, filed on May 7, 2015.
Prior Publication US 2020/0330447 A1, Oct. 22, 2020
Int. Cl. A61K 31/46 (2006.01); A61K 45/06 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01); A61K 31/4535 (2006.01)
CPC A61K 31/46 (2013.01) [A61K 31/4535 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A pharmaceutical mixture comprising:
deptropine or a pharmaceutically acceptable salt, stereoisomer, or enantiomer of deptropine, and
pizotifen or a pharmaceutically acceptable salt, stereoisomer, or enantiomer of pizotifen.